E Fund Management Co. Ltd. Has $223,000 Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

E Fund Management Co. Ltd. decreased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 9.4% in the 4th quarter, Holdings Channel reports. The fund owned 23,695 shares of the biopharmaceutical company’s stock after selling 2,472 shares during the period. E Fund Management Co. Ltd.’s holdings in Amicus Therapeutics were worth $223,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. OLD Second National Bank of Aurora bought a new stake in shares of Amicus Therapeutics in the third quarter worth $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Amicus Therapeutics during the 3rd quarter worth about $55,000. R Squared Ltd bought a new stake in shares of Amicus Therapeutics in the 4th quarter valued at about $79,000. KBC Group NV increased its stake in shares of Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 3,120 shares during the period. Finally, Stephens Inc. AR bought a new position in shares of Amicus Therapeutics during the fourth quarter worth about $101,000.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Morgan Stanley restated an “equal weight” rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. JPMorgan Chase & Co. boosted their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Finally, StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.75.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $8.86 on Monday. The firm has a market capitalization of $2.72 billion, a P/E ratio of -49.22, a P/E/G ratio of 1.51 and a beta of 0.69. Amicus Therapeutics, Inc. has a 52 week low of $8.78 and a 52 week high of $12.65. The stock has a 50 day moving average price of $9.43 and a two-hundred day moving average price of $10.24. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.